Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Application based on results from the TROPION-Breast01 Phase III trial
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Establishment of 220 smart classrooms across Uttar Pradesh, Uttarakhand, and Himachal Pradesh
Executes the first project for developing and manufacturing a novel anticancer mAb
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
Combination shows consistent benefit across prespecified post-progression outcomes
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
To accelerate the development of next-generation radioconjugates to treat cancer
Subscribe To Our Newsletter & Stay Updated
